Display options
Cite
Prayuenyong P, Baguley DM, Kros CJ, et al. Preferential Cochleotoxicity of Cisplatin. Front Neurosci. 2021;15:695268doi: 10.3389/fnins.2021.695268.
Prayuenyong, P., Baguley, D. M., Kros, C. J., & Steyger, P. S. (2021). Preferential Cochleotoxicity of Cisplatin. Frontiers in neuroscience, 15695268. https://doi.org/10.3389/fnins.2021.695268
Prayuenyong, Pattarawadee, et al. "Preferential Cochleotoxicity of Cisplatin." Frontiers in neuroscience vol. 15 (2021): 695268. doi: https://doi.org/10.3389/fnins.2021.695268
Prayuenyong P, Baguley DM, Kros CJ, Steyger PS. Preferential Cochleotoxicity of Cisplatin. Front Neurosci. 2021 Jul 26;15:695268. doi: 10.3389/fnins.2021.695268. eCollection 2021. PMID: 34381329; PMCID: PMC8350121.
Copy Download .nbib Format: NLM
Share it on

Front Neurosci. 2021 Jul 26;15:695268. doi: 10.3389/fnins.2021.695268. eCollection 2021.

Preferential Cochleotoxicity of Cisplatin.

Frontiers in neuroscience

Pattarawadee Prayuenyong, David M Baguley, Corné J Kros, Peter S Steyger

Affiliations

  1. Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
  2. Hearing Sciences, Division of Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  3. National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham, United Kingdom.
  4. Nottingham Audiology Services, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
  5. School of Life Sciences, University of Sussex, Brighton, United Kingdom.
  6. Translational Hearing Center, Biomedical Sciences, Creighton University, Omaha, NE, United States.

PMID: 34381329 PMCID: PMC8350121 DOI: 10.3389/fnins.2021.695268

Abstract

Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has been consistently reported in the current literature. Inner ear hair cells seem to have intrinsic characteristics that make them susceptible to direct exposure to cisplatin. The existing literature suggests, however, that cisplatin might have different patterns of drug trafficking across the blood-labyrinth-barrier, or different degrees of cisplatin uptake to the hair cells in the cochlear and vestibular compartments. This review proposes an explanation for the preferential cochleotoxicity of cisplatin based on current evidence as well as the anatomy and physiology of the inner ear. The endocochlear potential, generated by the stria vascularis, acting as the driving force for hair cell mechanoelectrical transduction might also augment cisplatin entry into cochlear hair cells. Better understanding of the stria vascularis might shed new light on cochleotoxic mechanisms and inform the development of otoprotective interventions to moderate cisplatin associated ototoxicity.

Copyright © 2021 Prayuenyong, Baguley, Kros and Steyger.

Keywords: cisplatin; cochlea; cochleotoxicity; ototoxicity; vestibular; vestibulotoxicity

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Neurotoxicology. 2017 May;60:1-9 - PubMed
  2. Physiology (Bethesda). 2006 Oct;21:336-45 - PubMed
  3. Brain Behav Evol. 2018;92(1-2):1-31 - PubMed
  4. Toxicol Appl Pharmacol. 2006 Sep 1;215(2):228-36 - PubMed
  5. Cancer. 2016 Jun 1;122(11):1647-58 - PubMed
  6. Mol Pharm. 2016 Aug 1;13(8):2677-82 - PubMed
  7. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2017 Dec 18;16:Doc02 - PubMed
  8. Am J Physiol Renal Physiol. 2009 Mar;296(3):F505-11 - PubMed
  9. Hear Res. 2003 Nov;185(1-2):49-56 - PubMed
  10. Acta Otolaryngol. 2011 Jun;131(6):624-7 - PubMed
  11. Otol Neurotol. 2021 Jul 1;42(6):e730-e734 - PubMed
  12. Audiol Neurootol. 2007;12(3):170-8 - PubMed
  13. Hear Res. 2001 May;155(1-2):1-8 - PubMed
  14. Front Oncol. 2018 Sep 25;8:363 - PubMed
  15. Toxicol Lett. 2015 Sep 17;237(3):219-27 - PubMed
  16. Cold Spring Harb Perspect Med. 2019 Nov 1;9(11): - PubMed
  17. Am J Physiol Cell Physiol. 2002 Feb;282(2):C403-7 - PubMed
  18. Laryngoscope. 2020 Sep;130(9):E515-E521 - PubMed
  19. Neuroscience. 2003;120(1):191-205 - PubMed
  20. J Neurosci. 2019 Apr 10;39(15):2951-2964 - PubMed
  21. J Otolaryngol. 1991 Jun;20(3):158-67 - PubMed
  22. J Clin Oncol. 2014 Feb 20;32(6):527-34 - PubMed
  23. Chem Res Toxicol. 2019 Aug 19;32(8):1469-1486 - PubMed
  24. Expert Opin Drug Metab Toxicol. 2020 Oct;16(10):965-982 - PubMed
  25. Semin Hear. 2019 May;40(2):197-204 - PubMed
  26. Laryngoscope. 1986 Sep;96(9 Pt 1):959-74 - PubMed
  27. Inorg Chem. 2017 Jun 5;56(11):6712-6724 - PubMed
  28. Toxics. 2015 Jul 15;3(3):268-293 - PubMed
  29. Toxicol Lett. 2016 Nov 16;262:49-54 - PubMed
  30. Int J Audiol. 2018 Sep;57(sup4):S34-S40 - PubMed
  31. Anat Rec (Hoboken). 2012 Nov;295(11):1851-67 - PubMed
  32. J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):710-5 - PubMed
  33. Hear Res. 2000 Nov;149(1-2):189-98 - PubMed
  34. Hear Res. 2013 Mar;297:42-51 - PubMed
  35. J Neurosci. 2009 Mar 25;29(12):3843-51 - PubMed
  36. Anat Rec (Hoboken). 2012 Nov;295(11):1837-50 - PubMed
  37. Hear Res. 2003 Aug;182(1-2):56-64 - PubMed
  38. Hear Res. 2002 Feb;164(1-2):138-46 - PubMed
  39. Hear Res. 2018 Apr;361:152-156 - PubMed
  40. Hear Res. 2013 May;299:37-45 - PubMed
  41. Laryngoscope. 2013 Dec;123(12):3172-7 - PubMed
  42. Front Neurol. 2017 Jun 09;8:258 - PubMed
  43. Radiol Oncol. 2019 Mar 28;53(2):148-158 - PubMed
  44. Neurotoxicol Teratol. 2015 Sep-Oct;51:12-20 - PubMed
  45. J Neurol. 2016 Apr;263 Suppl 1:S54-64 - PubMed
  46. Audiol Neurootol. 1997 May-Jun;2(3):155-67 - PubMed
  47. J Clin Oncol. 2016 Aug 10;34(23):2712-20 - PubMed
  48. PLoS One. 2015 Mar 20;10(3):e0120612 - PubMed
  49. Cancer Res. 2018 Jan 15;78(2):320-325 - PubMed
  50. Lancet Oncol. 2019 Jan;20(1):e29-e41 - PubMed
  51. J Assoc Res Otolaryngol. 2006 Sep;7(3):299-307 - PubMed
  52. Laryngoscope. 1996 Feb;106(2 Pt 1):162-7 - PubMed
  53. J Laryngol Otol. 2009 Feb;123(2):151-62 - PubMed
  54. J Clin Neurol. 2010 Jun;6(2):51-63 - PubMed
  55. Hear Res. 1995 Oct;90(1-2):149-57 - PubMed
  56. Nat Commun. 2017 Nov 21;8(1):1654 - PubMed
  57. J Clin Oncol. 2012 Jul 1;30(19):2408-17 - PubMed
  58. Clin Pharmacol Ther. 2017 Apr;101(4):491-500 - PubMed
  59. J Toxicol. 2016;2016:1809394 - PubMed
  60. J Assoc Res Otolaryngol. 2020 Aug;21(4):303-321 - PubMed
  61. Audiol Neurootol. 2019;24(5):253-257 - PubMed
  62. Hear Res. 2002 Mar;165(1-2):1-9 - PubMed
  63. Mol Pharmacol. 2006 Jul;70(1):23-9 - PubMed
  64. Neurology. 2005 Sep 27;65(6):898-904 - PubMed
  65. Biophys J. 2000 Nov;79(5):2572-82 - PubMed
  66. J Assoc Res Otolaryngol. 2021 Apr;22(2):107-126 - PubMed
  67. Naunyn Schmiedebergs Arch Pharmacol. 1995 Sep;352(3):247-55 - PubMed

Publication Types

Grant support